Instability Challenges and Stabilization Strategies of Pharmaceutical Proteins
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Maintaining the structure of protein and peptide drugs has become one of the most important goals of scientists in recent decades. Cold and thermal denaturation conditions, lyophilization and freeze drying, different pH conditions, concentrations, ionic strength, environmental agitation, the interaction between the surface of liquid and air as well as liquid and solid, and even the architectural structure of storage containers are among the factors that affect the stability of these therapeutic biomacromolecules. The use of genetic engineering, side-directed mutagenesis, fusion strategies, solvent engineering, the addition of various preservatives, surfactants, and additives are some of the solutions to overcome these problems. This article will discuss the types of stress that lead to instabilities of different proteins used in pharmaceutics including regulatory proteins, antibodies, and antibody-drug conjugates, and then all the methods for fighting these stresses will be reviewed. New and existing analytical methods that are used to detect the instabilities, mainly changes in their primary and higher order structures, are briefly summarized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The amyloid state and its association with protein misfolding diseases.
Knowles, T. P. J., Vendruscolo, M., & Dobson, C. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3810 · Cited by 2,382
The mechanism of action of cyclosporin A and FK506
Schreiber, S. L., & Crabtree, G. R. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90111-j · Cited by 2,127
Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy
Chari, R. V. J., Miller, M. L., & Widdison, W. C. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307628 · Cited by 930
Oxidation of methionyl residues in proteins: Tools, targets, and reversal
Vogt, W. (1995) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(94)00158-g · Cited by 883
Roher, A. E., Lowenson, J. D., Clarke, S., Wolkow, C., Wang, R., Cotter, R. J., Reardon, I. M., Zürcher-Neely, H. A., Heinrikson, R. L., & Ball, M. J. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53661-9 · Cited by 799
Therapeutic Protein–Polymer Conjugates: Advancing Beyond PEGylation
Pelegri-O’Day, E. M., Lin, E.-W., & Maynard, H. D. (2014) · Journal of the American Chemical Society · doi:10.1021/ja504390x · Cited by 622
Antibody–drug conjugates: Recent advances in linker chemistry
Su, Z., Xiao, D., Xie, F., Liu, L., Wang, Y., Fan, S., Zhou, X., & Li, S. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.042 · Cited by 403
VanderMolen, K. M., McCulloch, W., Pearce, C. J., & Oberlies, N. H. (2011) · The Journal of Antibiotics · doi:10.1038/ja.2011.35 · Cited by 333
Drucker, D. J., Dritselis, A., & Kirkpatrick, P. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3148 · Cited by 181
Hydrolysis of a peptide bond in neutral water
Kahne, D., & Still, W. C. (1988) · Journal of the American Chemical Society · doi:10.1021/ja00230a041 · Cited by 176
Cited by
Biolayer interferometry and its applications in drug discovery and development
Jug, A., Bratkovič, T., & Ilaš, J. (2024) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2024.117741 · Cited by 107
Integrating Computational Design and Experimental Approaches for Next-Generation Biologics
Son, A., Park, J., Kim, W., Lee, W., Yoon, Y., Ji, J., & Kim, H. (2024) · Biomolecules · doi:10.3390/biom14091073 · Cited by 29
Metadata
- Authors
- Akbarian, M., & Chen, S.-H.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2022-11-20
- Volume
- 14
- Issue
- 11
- Pages
- 2533
- ISSN
- 1999-4923 (ISSN-L)
- OpenAlex
- W4309737076
- Cited by
- 169
- References
- 11
- FWCI
- 7.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.